Literature DB >> 8612308

Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.

M Belanich1, T Randall, M A Pastor, J T Kibitel, L G Alas, M E Dolan, S C Schold, M Gander, F J Lejeune, B F Li, A B White, P Wasserman, M L Citron, D B Yarosh.   

Abstract

O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl adducts from DNA and may be important in tumor resistance to alkylation chemotherapy. MGMT was visualized in human cells and tumor tissues with monoclonal antibodies against MGMT and immunofluorescence microscopy, and fluorescent signals were quantified by digital image analysis. MGMT was found both in the cytoplasm and the nucleus, and in either locale the protein reacts with alkylated DNA bases and becomes inactivated and lost from the cell. Cell lines in culture and xenografts showed a broad normal distribution of nuclear MGMT levels, but human brain tumors often showed a skewed distribution, with a significant fraction of cells with high levels of MGMT. O(6)-Benzylguanine, a suicide substrate inactivator for MGMT activity, reduced MGMT in human cells and in a mouse xenograft to levels undetectable by antibody assay 1 h post-treatment. In melanoma specimens taken from a patient 3 h post-treatment with temozolomide, MGMT levels were reduced by 70%. This quantitative immunofluorescence assay can be used to monitor MGMT and it depletion in human tumors to improve the use of alkylating agents in cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612308     DOI: 10.1007/s002800050427

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Phase II trial of temozolomide in children with recurrent high-grade glioma.

Authors:  A Ruggiero; G Cefalo; M L Garré; M Massimino; C Colosimo; G Attinà; I Lazzareschi; P Maurizi; V Ridola; G Mazzarella; M Caldarelli; C Di Rocco; E Madon; M E Abate; A Clerico; A Sandri; R Riccardi
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

2.  MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.

Authors:  Er Nie; Xin Jin; Weining Wu; Tianfu Yu; Xu Zhou; Zhumei Shi; Junxia Zhang; Ning Liu; Yongping You
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

3.  Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.

Authors:  Asia Asiaf; Shiekh Tanveer Ahmad; Ajaz Ahmad Malik; Shiekh Aejaz Aziz; Zubaida Rasool; Akbar Masood; Mohammad Afzal Zargar
Journal:  Tumour Biol       Date:  2015-03-29

Review 4.  Optimal role of temozolomide in the treatment of malignant gliomas.

Authors:  Roger Stupp; Martin J van den Bent; Monika E Hegi
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

5.  The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions.

Authors:  Zhenhua Lin; Meihua Gao; Xianglan Zhang; Young-Sik Kim; Eung-Seok Lee; Han-Kyeom Kim; Insun Kim
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-23       Impact factor: 4.553

Review 6.  The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective.

Authors:  Jonathan L Finlay; Stergios Zacharoulis
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

7.  Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

Authors:  K A van Nifterik; J van den Berg; W F van der Meide; N Ameziane; L E Wedekind; R D M Steenbergen; S Leenstra; M V M Lafleur; B J Slotman; L J A Stalpers; P Sminia
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

Review 8.  Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Authors:  Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards.

Authors:  Rachel L Loeber; Erin D Michaelson-Richie; Simona G Codreanu; Daniel C Liebler; Colin R Campbell; Natalia Y Tretyakova
Journal:  Chem Res Toxicol       Date:  2009-06       Impact factor: 3.739

Review 10.  MGMT testing--the challenges for biomarker-based glioma treatment.

Authors:  Wolfgang Wick; Michael Weller; Martin van den Bent; Marc Sanson; Markus Weiler; Andreas von Deimling; Christoph Plass; Monika Hegi; Michael Platten; Guido Reifenberger
Journal:  Nat Rev Neurol       Date:  2014-06-10       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.